Navigation Links
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Date:12/11/2007

ater than 70 years of age, and demonstrated the safety profile of rosiglitazone to be consistent with the control medicine (sulfonylurea).

Importantly, the results of this study do not reproduce what is already known about the risk of CHF in TZD users. TZDs can cause fluid retention which can lead to or exacerbate heart failure. TZDs also have a similar increased risk of CHF. Yet, in this analysis, pioglitazone is not associated with an increased risk of CHF (Adjusted RR of 0.91 (95% CI = 0.52-1.59) whereas rosiglitazone is associated with 2 fold-increased risk of CHF (Adjusted RR = 1.98 and 95% CI=1.44-2.72) compared to oral anti-diabetic combination therapy. This is inconsistent with the product labeling.

Moreover, the authors of this retrospective analysis fail to acknowledge the findings of large epidemiological studies, encompassing over 1.3 million patients with type 2 diabetes, as well as other similar studies presented during the recent FDA Advisory Committee meeting. These studies have investigated whether use of rosiglitazone in the real world setting is associated with an increase in myocardial infarction or coronary revascularization. The majority of these studies show that rosiglitazone is not associated with an increased risk of myocardial infarction compared to other anti-diabetic agents.

GSK cites the following as examples of the limitations of this retrospective analysis:

-- As the authors state, patients on TZDs in their analysis may represent

an older, select group of patients with advanced diabetes and therefore

higher baseline risk for cardiovascular disease.

-- The ODB database is composed of a select group of patients.

Rosiglitazone is only prescribed for those patients who fail

treatment on metformin and sulfonylurea, or for whom sulfonylurea or

metformin are contraindicated. The rosiglitazone patients are

therefore ones with higher
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
9. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
10. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 01, 2015 Shimadzu Corporation announced ... Unified Chromatography system (Nexera UC) received the Pittcon ... on Analytical Chemistry and Applied Spectroscopy (Pittcon) held ... 12th. , The Pittcon Editors’ Awards recognize ... the first time based on votes by the ...
(Date:4/1/2015)... 2015  VLP Therapeutics, LLC. ("VLP"), a ... and development of therapeutic and preventative vaccines and next ... vaccine technology, today announced that it has entered into a ... Nagasaki University in ... and development of dengue vaccine candidates. ...
(Date:4/1/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... to announce that Biohaven Pharmaceutical Holding Company Limited ... into an agreement with inVentiv Health for the ... their lead compound (BHV-0223). Biohaven ... clinical stage neuroscience compounds targeting the glutamatergic system. ...
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/8dzk58/blood_screening ) ... Screening Market by Technology (Nucleic Acid Amplification Test, ... Western Blotting), Product (Instrument, Reagent) & End User ... report to their offering. The ... billion by 2019 from $1.5 billion in 2014, ...
Breaking Biology Technology:Shimadzu Nexera UC Recognized at Pittcon 2015 with Editors’ Gold Award 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3
... AMSTERDAM, October 13 Amsterdam ... human gene therapy,announced today that the European Medicines Agency ... AMT-080 for the treatment of,Duchenne muscular dystrophy. , ... dystrophy (DMD) entitles,AMT to ten year market exclusivity in ...
... Chopra ... Stephanie Simonton, have created "Return to Wholeness: A Mind-body Approach to Healing Cancer" ... to strengthen their immune system, reduce the side effects of treatment, and awaken the ... ...
... BOZEN, Italy, October 12 ... installation of the first,five i.v.STATION post-prototype robots in the ... to November timeframe this year; concurrently,Health Robotics also made ... Science Park 3L 3T Innovation Award, which is given ...
Cached Biology Technology:AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 3Healing Cancer Through Mind-Body Medicine: The Chopra Center Releases Pioneering DVD for Every Stage of Treatment 2Healing Cancer Through Mind-Body Medicine: The Chopra Center Releases Pioneering DVD for Every Stage of Treatment 3Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award 2Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award 3
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:4/2/2015)... , April 2, 2015 ... touch fingerprint sensor FPC1025 from the distributor World Peace ... commence during Q2 2015 although the major part of ... sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... CAMBRIDGE, MA -- Earthworms creep along the ground by ... their bodies, inching forward with each wave of contractions. ... peristalsis, to get around, and our own gastrointestinal tracts ... esophagus to push food to the stomach. Now ...
... Rochelle, NY, August 9, 2012Despite criticism from Congressional Republicans ... Rim of the Pacific (RIMPAC) 2012 international maritime exercises, ... biofuels blend. The Navy contends that renewable energy resources ... in enhancing national security and energy independence. Tom Hicks, ...
... trees are one of the biggest contributors to air ... chemicals many of which are produced by human ... air. New research from a team led by Carnegie ... formed from pine tree emissions are much more chemically ...
Cached Biology News:Soft autonomous robot inches along like an earthworm 2Soft autonomous robot inches along like an earthworm 3US Navy defends renewable fuels strategy in Industrial Biotechnology Journal 2Carnegie Mellon study shows skin-aging radicals age naturally formed particles in the air 2Carnegie Mellon study shows skin-aging radicals age naturally formed particles in the air 3
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Immunochemistry 1 & 2...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: